ERAP2 and neoplasm: Analysis of the staining scores revealed that strong staining (2+ and 3+) for AGRN, CTSC, ERAP2, and GPNMB was respectively detected in 20.4% (20/98), 32.3% (32/99), 83.7% (82/98), and 56% (56/100) of regions containing tumor cells, while weak staining (1+) was respectively detected in 91.8% (90/98), 94.9% (94/99), 40.8% (40/98), and 99% (99/100) of regions harboring paired adjacent non-tumor cells (Figure 6B).